Stem definition | Drug id | CAS RN |
---|---|---|
monoamine oxydase (MAO)-inhibitors type B | 2429 | 14611-51-9 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.89 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 4.40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 1.90 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.30 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 5, 1989 | FDA | SOMERSET |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site rash | 180.02 | 28.77 | 35 | 1600 | 2322 | 50601167 |
Application site erythema | 168.21 | 28.77 | 37 | 1598 | 4501 | 50598988 |
Application site pruritus | 97.89 | 28.77 | 23 | 1612 | 3736 | 50599753 |
Application site reaction | 83.12 | 28.77 | 15 | 1620 | 659 | 50602830 |
Dyskinesia | 79.89 | 28.77 | 31 | 1604 | 27830 | 50575659 |
Application site urticaria | 75.13 | 28.77 | 12 | 1623 | 250 | 50603239 |
Hallucination | 73.78 | 28.77 | 34 | 1601 | 46623 | 50556866 |
Hallucination, visual | 67.96 | 28.77 | 24 | 1611 | 16558 | 50586931 |
Parkinsonism hyperpyrexia syndrome | 67.34 | 28.77 | 10 | 1625 | 126 | 50603363 |
Application site irritation | 58.84 | 28.77 | 13 | 1622 | 1602 | 50601887 |
Drug interaction | 36.15 | 28.77 | 38 | 1597 | 199583 | 50403906 |
Application site pain | 29.80 | 28.77 | 9 | 1626 | 3789 | 50599700 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hallucination | 154.61 | 30.44 | 74 | 2299 | 44638 | 29527516 |
Dyskinesia | 123.91 | 30.44 | 50 | 2323 | 20011 | 29552143 |
Hypersexuality | 84.47 | 30.44 | 20 | 2353 | 1336 | 29570818 |
Hallucination, visual | 84.36 | 30.44 | 35 | 2338 | 14980 | 29557174 |
Impulse-control disorder | 81.20 | 30.44 | 19 | 2354 | 1206 | 29570948 |
Gambling disorder | 76.45 | 30.44 | 19 | 2354 | 1556 | 29570598 |
Dopamine dysregulation syndrome | 73.90 | 30.44 | 14 | 2359 | 315 | 29571839 |
On and off phenomenon | 67.84 | 30.44 | 18 | 2355 | 1910 | 29570244 |
Application site rash | 67.61 | 30.44 | 15 | 2358 | 749 | 29571405 |
Delusion | 62.49 | 30.44 | 26 | 2347 | 11190 | 29560964 |
Application site erythema | 43.70 | 30.44 | 13 | 2360 | 2086 | 29570068 |
Parkinsonism hyperpyrexia syndrome | 41.31 | 30.44 | 7 | 2366 | 81 | 29572073 |
Impulsive behaviour | 31.79 | 30.44 | 10 | 2363 | 1933 | 29570221 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hallucination | 171.98 | 27.23 | 81 | 3266 | 72707 | 64422678 |
Application site rash | 163.99 | 27.23 | 34 | 3313 | 1920 | 64493465 |
Dyskinesia | 159.04 | 27.23 | 64 | 3283 | 39324 | 64456061 |
Hallucination, visual | 147.06 | 27.23 | 55 | 3292 | 27779 | 64467606 |
Application site erythema | 129.43 | 27.23 | 33 | 3314 | 4656 | 64490729 |
Parkinsonism hyperpyrexia syndrome | 106.50 | 27.23 | 17 | 3330 | 213 | 64495172 |
Impulse-control disorder | 95.50 | 27.23 | 21 | 3326 | 1567 | 64493818 |
Gambling disorder | 86.47 | 27.23 | 20 | 3327 | 1874 | 64493511 |
Hypersexuality | 85.85 | 27.23 | 19 | 3328 | 1460 | 64493925 |
Dopamine dysregulation syndrome | 74.73 | 27.23 | 14 | 3333 | 465 | 64494920 |
Delusion | 71.66 | 27.23 | 29 | 3318 | 17985 | 64477400 |
Application site pruritus | 60.20 | 27.23 | 17 | 3330 | 3522 | 64491863 |
Application site urticaria | 50.20 | 27.23 | 9 | 3338 | 233 | 64495152 |
Application site irritation | 43.02 | 27.23 | 11 | 3336 | 1565 | 64493820 |
On and off phenomenon | 42.39 | 27.23 | 12 | 3335 | 2507 | 64492878 |
Muscle rigidity | 36.74 | 27.23 | 18 | 3329 | 17455 | 64477930 |
Orthostatic hypotension | 35.82 | 27.23 | 25 | 3322 | 46713 | 64448672 |
Insomnia | 31.95 | 27.23 | 45 | 3302 | 197791 | 64297594 |
Sudden onset of sleep | 30.91 | 27.23 | 7 | 3340 | 596 | 64494789 |
Psychotic disorder | 30.07 | 27.23 | 20 | 3327 | 34558 | 64460827 |
Drug interaction | 29.89 | 27.23 | 61 | 3286 | 362022 | 64133363 |
Application site reaction | 29.72 | 27.23 | 7 | 3340 | 708 | 64494677 |
Sleep talking | 27.29 | 27.23 | 7 | 3340 | 1008 | 64494377 |
None
Source | Code | Description |
---|---|---|
ATC | N04BD01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors |
FDA MoA | N0000000184 | Monoamine Oxidase Inhibitors |
MeSH PA | D018726 | Anti-Dyskinesia Agents |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D000978 | Antiparkinson Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
MeSH PA | D018696 | Neuroprotective Agents |
MeSH PA | D020011 | Protective Agents |
MeSH PA | D011619 | Psychotropic Drugs |
CHEBI has role | CHEBI:176497 | geroprotectors |
CHEBI has role | CHEBI:38623 | monoamine oxidase inhibitors |
CHEBI has role | CHEBI:48407 | antiparkinson agent |
CHEBI has role | CHEBI:48560 | dopaminergic agents |
FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
FDA MoA | N0000175761 | Monoamine Oxidase-B Inhibitors |
FDA EPC | N0000175762 | Monoamine Oxidase Type B Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Parkinson's disease | indication | 49049000 | DOID:14330 |
Major depressive disorder | indication | 370143000 | |
Suicidal thoughts | contraindication | 6471006 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Orthostatic hypotension | contraindication | 28651003 | |
Conduction disorder of the heart | contraindication | 44808001 | |
Psychotic disorder | contraindication | 69322001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Tardive dyskinesia | contraindication | 102449007 | |
Angina pectoris | contraindication | 194828000 | |
Mania | contraindication | 231494001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pheochromocytoma | contraindication | 302835009 | |
Malignant melanoma | contraindication | 372244006 |
Species | Use | Relation |
---|---|---|
Dogs | Cognitive dysfunction syndrome (CDS) | Indication |
Dogs | Pituitary dependent hyperadrenocorticism (PDH) | Indication |
Product | Applicant | Ingredients |
---|---|---|
Anipryl | Zoetis Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.6 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 7.26 | CHEMBL | CHEMBL | |||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.76 | DRUG MATRIX | |||||
Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.04 | CHEMBL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
Alpha-synuclein | Transporter | IC50 | 6.57 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.87 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.98 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.42 | CHEMBL | |||||
Amine oxidase [flavin-containing] B | Enzyme | Ki | 6.01 | CHEMBL | |||||
Monoamine oxidase | Enzyme | IC50 | 7.89 | CHEMBL |
ID | Source |
---|---|
4019929 | VUID |
N0000148014 | NUI |
D00785 | KEGG_DRUG |
14611-52-0 | SECONDARY_CAS_RN |
4019485 | VANDF |
4019929 | VANDF |
C0036579 | UMLSCUI |
CHEBI:50217 | CHEBI |
CHEMBL972 | ChEMBL_ID |
DB01037 | DRUGBANK_ID |
CHEMBL1200904 | ChEMBL_ID |
D012642 | MESH_DESCRIPTOR_UI |
26757 | PUBCHEM_CID |
4436 | INN_ID |
6639 | IUPHAR_LIGAND_ID |
2K1V7GP655 | UNII |
203137 | RXNORM |
1551 | MMSL |
21238 | MMSL |
53269 | MMSL |
5448 | MMSL |
63129 | MMSL |
d00976 | MMSL |
003465 | NDDF |
004599 | NDDF |
108466000 | SNOMEDCT_US |
108467009 | SNOMEDCT_US |
372497003 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
ZELAPAR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0453 | TABLET, ORALLY DISINTEGRATING | 1.25 mg | ORAL | NDA | 25 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-737 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Selegiline Hydrochloride | Human Prescription Drug Label | 1 | 16571-659 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-900 | PATCH | 6 mg | TRANSDERMAL | NDA | 31 sections |
EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-901 | PATCH | 9 mg | TRANSDERMAL | NDA | 31 sections |
EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-902 | PATCH | 12 mg | TRANSDERMAL | NDA | 31 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-2918 | TABLET | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-176 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-0055 | CAPSULE | 5 mg | ORAL | ANDA | 13 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-3438 | TABLET | 5 mg | ORAL | ANDA | 20 sections |
SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2649 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | Human Prescription Drug Label | 1 | 70954-504 | CAPSULE | 5 mg | ORAL | ANDA | 20 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71205-888 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71205-888 | CAPSULE | 5 mg | ORAL | ANDA | 19 sections |
Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72319-006 | TABLET | 5 mg | ORAL | ANDA | 15 sections |